Get the Stockscreener App
2.5925
2.47%
0.0625
Neurobo Pharmaceuticals Inc stock is traded at $2.5925, with a volume of 14,701.
It is up +2.47% in the last 24 hours and down -5.04% over the past month.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
See More
Previous Close:
$2.53
Open:
$2.72
24h Volume:
14,701
Relative Volume:
0.35
Market Cap:
$22.49M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.292
EPS:
-8.877
Net Cash Flow:
$-10.85M
1W Performance:
-9.35%
1M Performance:
-5.04%
6M Performance:
-31.42%
1Y Performance:
+517.26%
1-Day Range:
$2.5672
$2.74
1-Week Range:
$2.41
$2.9783
52-Week Range:
$0.38
$6.7499
Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile
Name
Neurobo Pharmaceuticals Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE, MA
Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
Neurobo Pharmaceuticals Inc Stock (NRBO) Latest News
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research
NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa
NeuroBo reports positive early trial results for obesity drug - Investing.com
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance
NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency
Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat
Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance
BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com
Lombard Odier Asset Management Europe Ltd Reduces Stock Position in nVent Electric plc (NYSE:NVT) - Defense World
Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Increases Dividend to $0.81 Per Share - MarketBeat
Amalgamated Bank Reduces Holdings in nVent Electric plc (NYSE:NVT) - Defense World
Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com
BMO sustains stock target, outperform on Novo Nordisk amid trial results - Investing.com India
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results - Investopedia
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Yahoo Finance
Novo Nordisk Shares Slide After Disappointing Obesity Pill Trial - Finimize
Novo Nordisk shares drop more than 4% on disappointing obesity pill data - The Economic Times
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear? - Yahoo Finance
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update - StreetInsider.com
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data - Yahoo Finance
Novo Shares Fall on Safety Data for New Weight-Loss Drug - BNN Bloomberg
Novo drops to 1-month low after Monlunabant trial data - XM
NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Australia
NeuroBo shareholders approve significant stock issuance - Investing.com India
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential (NYSE:NVO) - Seeking Alpha
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Clinical Trials Arena
NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial - TipRanks
NeuroBo partners for long-acting obesity treatment - Investing.com India
NeuroBo Partners for Monthly Dual-Action Diabetes Drug Development - TipRanks
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - StockTitan
NeuroBo licenses diabetic neuropathy drug to MThera Pharma By Investing.com - Investing.com Nigeria
NeuroBo licenses diabetic neuropathy drug to MThera Pharma - Investing.com
NeuroBo Signs Exclusive License Agreement With MTHERA For NB-01 - Contract Pharma
NeuroBo Pharmaceuticals Strikes Licensing Deal for NB-01 - TipRanks
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Down 3.4% - Defense World
BIX 2024: From graveyard to breakthrough, MASH candidates on rise - BioWorld Online
Neurobo Pharmaceuticals Inc Stock (NRBO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):